Amy Parison serves as Senior Vice President and Chief Financial Officer at Editas Medicine Inc., a leading gene editing company pioneering CRISPR-based therapies for serious diseases. In this pivotal role, she oversees all financial operations, including strategic planning, investor relations, capital raising, and financial reporting. Parison plays a critical part in steering the company's growth amid the dynamic biotech landscape, ensuring fiscal discipline while supporting innovative pipeline advancement, such as the development of EDIT-101 for Leber congenital amaurosis. With over two decades of experience in the biotechnology and pharmaceutical industries, Parison brings a proven track record of financial leadership at public companies. Prior to joining Editas in 2021, she was Chief Financial Officer at bluebird bio, where she managed global finance functions during a period of significant clinical and commercial expansion. Before that, she held senior finance positions at Alkermes plc, including Senior Vice President of Finance and Treasurer, contributing to multiple financings and operational efficiencies. Earlier in her career, Parison worked at Genzyme Corporation (now part of Sanofi) in various finance and business development roles. Parison's achievements include orchestrating successful equity offerings, debt financings, and mergers that have fueled biotech innovation, earning her recognition as a strategic financial leader. At Editas, she has been instrumental in navigating capital markets challenges, optimizing cash runway, and fostering partnerships that advance the company's mission to treat genetic diseases. A certified public accountant with a B.S. in Accounting from Bentley University, Parison is committed to driving sustainable value creation in precision medicine.